Invion Ltd Quarterly Activities Report for June 2026
Key points
- Dr Colin Hopper appointed as Clinical Advisor to strengthen clinical governance
- Partnership with SANGMYUNG expands Photosoft into wet AMD market
- INV043 clinical trial expanded into Basal Cell Carcinoma (BCC) cohort
- Positive outlook for future trials and partnerships
Full summary
Invion Limited (ASX: IVX) has released its Quarterly Activities Report for the period ended 30 June 2026. Key highlights include the appointment of Dr Colin Hopper as Clinical Advisor, enhancing clinical governance and later-stage development capability. Invion also expanded its partnership with SANGMYUNG, entering the wet AMD market with non-dilutive funding. The INV043 clinical trial program expanded into Basal Cell Carcinoma (BCC), showing promising safety and efficacy signals. Invion expects to receive at least $440K from R&D tax incentives and has flexibility to adjust clinical study progression to align with cash inflows.
Guidance
Invion expects to receive at least $440K from R&D tax incentives for FY25 and FY26.
Outlook
Invion is well-positioned to continue advancing its proprietary technology across multiple clinical and pre-clinical programs.
Summary generated by a large language model. Please interpret with care.